Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT06872736
Recruiting Phase 2/3

Wereables for Upper Limb Functionality in Hemiparesis

NCT06872736 · tracked via the Priya Life Science Spain tracker
Phase
Phase 2/3
Started
2024-06-07
Last updated
2025-03-12

Condition(s) studied

Unilateral Cerebral Palsy

Investigational drug(s) / intervention(s)

WeFun-wearable activatedWeFun-wearable desactivated

WeFun-wearable activated: 1 month daily routine program with weekly visits in natural environments (home, community, etc) together with WeFun-weareable to increase spontaneous use of the upper limb in children with UCP during activities of daily life and leisure. Activities are priorized by Canadian Occupational Performance Measure and Goal Atteinment Scale. Programs are designed together with a transdisciplinary team, acting as consultants. Children in the experimental group will have the wearable's experimental movement functions activated.

WeFun-wearable desactivated: 1 month daily routine program with weekly visits in natural environments (home, community, etc) together with WeFun-weareable to increase spontaneous use of the upper limb in children with UCP during activities of daily life and leisure. Activities are priorized by Canadian Occupational Performance Measure and Goal Atteinment Scale. Programs are designed together with a transdisciplinary team, acting as consultants. Children in the control group will not have experimental functions in their wearables.

Study summary

The project is configured as a national interventional study that aims to determine the effectiveness of an intervention strategy using wearable technology, tailored to improve function (WeFun-wearable), on the spontaneous use of the affected upper extremity, activities of daily living and the participation in children with unilateral cerebral palsy.

Eligibility

Sex
ALL
Min age
3 Years
Max age
8 Years
Healthy volunteers
No
Inclusion Criteria: * Confirmed diagnosis of UCP. * Children aged between 3 and 8 years old. * Children rated on levels I to III on the Manual Ability Classification System (MACS). Exclusion Criteria: * Botulinum toxin injection or surgical interventions in the upper limb within 6 months prior to study entry. * Medical complications non-controlled that would interfere with study participation (e.g., not controlled epilepsy). * Predominantly athetoid or dystonia movement patterns. * Insufficient cognitive level to follow instructions, * Non-corrected marked visual impairments. Families can be retired from the study after starting if: * Families don't assist or don't collaborate in the weekly sessions with the reference person. * Wearable activity if presumably lower than expected (few recordings of activity, \<20%). * Families don't provide feedback about daily sessions through the satisfaction system in the app/registration sheet.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Universidade da Coruña A Coruña A Coruña Recruiting

More Universidade da Coruña trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06872736 on ClinicalTrials.gov ↗ ← All trials in Spain